FDA OKs telmisartan for hypertension
The Food and Drug Administration (FDA)approved the angiotensin II receptor blocker, telmisartan (Boehringer Ingelheim’s Micardis), for the management of hypertensive patients. In clinical trials, a once-daily dose of telmisartan effectively controlled hypertension in up to 65% of patients and has been shown to be effective when compared to treatment with amlodipine, enalapril, and losartan. The drug was well toler-ated, with the incidence of adverse effects similar to that seen in patients receiving placebos.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content